Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
Journals
JPM
Special Issues
Personalized Diagnosis and Treatment of Urological Diseases
share announcement

Personalized Diagnosis and Treatment of Urological Diseases

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: 25 June 2025 | Viewed by 1376

Special Issue Editors

Dr. Alexandru Ciudin

E-Mail Website
Guest Editor
Urology Department, Hospital Universitari de Mollet, 08100 Barcelona, Spain
Interests: urology; urinary tract infections; prostate cancer; kidney stones
Dr. Lluís Peri

E-Mail Website
Guest Editor
Urology Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain
Interests: urology; urinary tract infections; prostate cancer; kidney stones

Special Issue Information

Dear Colleagues,

Background:

The field of urology has undergone significant transformation in recent years, with advances in diagnostic technologies and therapeutic approaches paving the way for more personalized care. Precision medicine is now playing a pivotal role in this field, offering tailored treatments that are specific to the genetic, environmental, and lifestyle factors of individual patients.

History:

Historically, the treatment of urological diseases relied on generalized protocols, often resulting in varied outcomes. With the advent of molecular diagnostics and novel drug delivery systems, personalized therapy has revolutionized the management of conditions such as prostate cancer, benign prostatic hyperplasia (BPH), and recurrent urinary tract infections.

Aim and Scope:

This Special Issue aims to explore cutting-edge advancements in the personalized diagnosis and treatment of urological diseases. The focus will be on integrating clinical, genomic, and imaging data to develop tailored therapies and on how drug delivery systems can be optimized for individualized care.

Cutting-edge Research:

We are particularly interested in research that bridges the gap between novel diagnostic tools, such as AI-based imaging or biomarkers, and therapeutic interventions, including gene therapy, targeted drug delivery, and the application of 3D printing in urology.

Papers of Interest:

We welcome original research and comprehensive reviews that address personalized diagnostic techniques, innovative drug delivery systems, and therapeutic approaches in urology. Contributions that demonstrate translational applications and patient-centered outcomes are highly encouraged.

Dr. Alexandru Ciudin
Dr. Lluís Peri
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized medicine
  • urological diseases
  • targeted therapy
  • drug delivery systems
  • precision urology
  • molecular diagnostics
  • biomarkers in urology
  • AI-based imaging
  • gene therapy
  • urological diagnostic techniques

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 265 KiB  
Article
Prostatic Artery Embolization in Elderly Comorbid Patients with Benign Prostatic Hyperplasia: Safety, Efficacy, and Predictive Factors of Clinical Failure
by Federico Zorzi, Giulio Rossin, Michelangelo Digregorio, Simone Lavecchia, Andrea Piasentin, Fabio Traunero, Carmelo Morreale, Michele Rizzo, Tommaso Cai, Carlo Trombetta, Alessandro Zucchi and Giovanni Liguori
J. Pers. Med. 2025, 15(1), 23; https://doi.org/10.3390/jpm15010023 - 10 Jan 2025
Viewed by 1108
Abstract
Background: This study aims to evaluate the safety and efficacy of prostatic artery embolization (PAE) in elderly, multimorbid patients with benign prostatic hyperplasia (BPH). Additionally, it seeks to identify technical and clinical factors that predict clinical failure at the mid-term follow-up. Methods [...] Read more.
Background: This study aims to evaluate the safety and efficacy of prostatic artery embolization (PAE) in elderly, multimorbid patients with benign prostatic hyperplasia (BPH). Additionally, it seeks to identify technical and clinical factors that predict clinical failure at the mid-term follow-up. Methods: We analyzed the clinical records of 175 consecutive patients who underwent PAE. Technical success was defined as achieving embolization on at least one side. Safety was assessed using the Clavien–Dindo classification. The pre-procedural international prostate symptom score (IPSS), quality of life (QoL) score, prostate volume (PV), prostate-specific antigen (PSA), maximum urinary flow rate (Qmax), and post-void residual urine (PVR) were compared with values assessed at the follow-up evaluation. Clinical failure was defined as no improvement or worsening of lower urinary tract symptoms (LUTS) based on the IPSS at the follow-up evaluation. Univariate and multivariate regression models were applied to identify predictors of clinical failure. Results: 158 patients met the inclusion criteria. The median age was 74 years (68, 79), with a median ASA score of 2 (2, 3) and a Charlson comorbidity index (CCI) of 5 (4, 7). Follow-up assessments were carried out at a median of 12 months (0, 1). IPSS decreased by −5 points (−8, 0), QoL by −1 point (−1, 0), PV by −19 cc (−26, −8), PVR by −45 cc (−25 to −80), and PSA by −1.1 ng/mL (−2.5, −0.2) (p < 0.01); while Qmax improved by 4 mL/s (2, 6) (p < 0.01). A total of 44 patients (30.3%) experienced clinical failure, which was significantly correlated with unilateral embolization (p < 0.01). Multivariate regression analysis indicated that higher CCI, elevated PVR, and the use of larger microspheres were associated with poorer clinical outcomes, with odds ratios of 2.17 (95% CI: 1.4–3.38), 1.02 (95% CI: 1.01–1.03), and 26.83 (95% CI: 4.81–149.8), respectively (p < 0.01). Conclusions: PAE is a safe and effective treatment for elderly multimorbid patients with BPH. Comprehensive pre-procedural clinical assessment, incorporating the CCI and PVR, is essential to optimize treatment outcomes. Full article
(This article belongs to the Special Issue Personalized Diagnosis and Treatment of Urological Diseases)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop